Literature DB >> 16980199

Insulin resistance in hypertension and cardiovascular disease.

Valéria Lamounier-Zepter1, Monika Ehrhart-Bornstein, Stefan R Bornstein.   

Abstract

Insulin resistance is not simply a problem of decreased glucose uptake in response to insulin, but a multifaceted syndrome that significantly increases the risk for cardiovascular disease. Insulin resistance is strongly associated with arterial hypertension and a pathogenetic role in the development of arterial hypertension has been suggested. One question that remains open concerns the clinical approach to insulin-resistant patients. Observational and clinical trial data suggest that lifestyle changes including weight reduction and regular physical activity can improve insulin sensitivity and reduce the incidence and mortality of cardiovascular disease. Daily physical activity of moderate intensity for 30 min has a cardioprotective effect and reduces insulin resistance, independent of the effect on body weight. A pharmacological therapy for insulin resistance reducing cardiovascular disease remains to be defined. Concerning the antihypertensive therapy of insulin-resistant hypertensive patients, most hypertensive guidelines fail to provide specific advice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980199     DOI: 10.1016/j.beem.2006.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  9 in total

1.  Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division.

Authors:  Dan Ye; FengQin Dong; XunLiang Lu; Zhe Zhang; YunFei Feng; ChengJiang Li
Journal:  Endocrine       Date:  2012-01-03       Impact factor: 3.633

2.  Primary non-alcoholic fatty liver disease in hypertensive patients.

Authors:  Luminita Latea; Stefania Negrea; Sorana Bolboaca
Journal:  Australas Med J       Date:  2013-06-30

3.  Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Sean Thatcher; Richard Charnigo; Debra L Rateri; Alan Daugherty; Lisa A Cassis
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

4.  Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes.

Authors:  Lindsey M Duca; David M Maahs; Irene E Schauer; Bryan C Bergman; Kristen J Nadeau; Petter Bjornstad; Marian Rewers; Janet K Snell-Bergeon
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

5.  Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: effects on some selected metabolic parameters.

Authors:  Silindile I Hadebe; Phikelelani S Ngubane; Metse R Serumula; Cephas T Musabayane
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 6.  Metabolic syndrome: is equine disease comparable to what we know in humans?

Authors:  Antonia Ertelt; Ann-Kristin Barton; Robert R Schmitz; Heidrun Gehlen
Journal:  Endocr Connect       Date:  2014-06-03       Impact factor: 3.335

Review 7.  β-Adrenergic Receptor and Insulin Resistance in the Heart.

Authors:  Supachoke Mangmool; Tananat Denkaew; Warisara Parichatikanond; Hitoshi Kurose
Journal:  Biomol Ther (Seoul)       Date:  2017-01-01       Impact factor: 4.634

Review 8.  A Mixed Comparisons of Aerobic Training With Different Volumes and Intensities of Physical Exercise in Patients With Hypertension: A Systematic Review and Network Meta-Analysis.

Authors:  Zhenghui Lu; Yang Song; Hairong Chen; Shudong Li; Ee-Chon Teo; Yaodong Gu
Journal:  Front Cardiovasc Med       Date:  2022-01-21

9.  The association of triglyceride and glucose index, and triglyceride to high-density lipoprotein cholesterol ratio with prehypertension and hypertension in normoglycemic subjects: A large cross-sectional population study.

Authors:  Fomin Zhang; Yingyi Zhang; Zhigang Guo; Hua Yang; Min Ren; Xiaomeng Xing; Hongliang Cong
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-12       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.